Hepatitis B Virus Core Promoter Double Mutations (A1762T, G1764A) Are Associated with Lower Levels of Serum Dihydrolipoyl Dehydrogenase.
OBJECTIVE
The aim of this study was to identify serum proteins with differential concentrations between hepatocellular carcinoma (HCC) patients and HBsAg asymptomatic carriers among individuals infected with hepatitis B virus (HBV) with basal core promoter (BCP) double mutations (A1762T, G1764A).


METHODS
iTRAQ and liquid chromatography-tandem mass spectrometry were used to identify differentially expressed protein, and an ELISA test was used for the validation test.


RESULTS
The total number of proteins identified was 1,125, of which 239 showed statistically significant differences in their expression. The relative concentrations of serum dihydrolipoyl dehydrogenase (DLD), which showed the most significant correlation with liver diseases and infection, were significantly lower in HCC patients than asymptomatic HBsAg carriers and individuals negative for HBsAg. However, only the difference between HCC patients with BCP double mutations and HBsAg-negative individuals could be confirmed by ELISA. Meanwhile, we found that the concentrations of serum DLD in those infected with HBV with BCP double mutations were significantly lower than in individuals with the wild-type BCP. However, the difference in the concentrations of serum DLD between individuals with wild-type BCP and those negative for HBsAg was not significant.


CONCLUSIONS
HBV with BCP double mutations are associated with lower concentrations of serum DLD.
Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control, Guangxi Key Laboratory for the Prevention and Control of Viral Hepatitis, Nanning, Guangxi, PR China.
Zhi-Hua
ZH
Jiang
Qin-Yan
QY
Chen
Tim J
TJ
Harrison
Guo-Jian
GJ
Li
Xue-Yan
XY
Wang
Hai
H
Li
Li-Ping
LP
Hu
Kai-Wen
KW
Li
Qing-Li
QL
Yang
Chao
C
Tan
Zhong-Liao
ZL
Fang
D000328:Adult; D058345:Asymptomatic Infections; D006528:Carcinoma, Hepatocellular / Q000201:enzymology / Q000821:virology*; D008058:Dihydrolipoamide Dehydrogenase / Q000097:blood*; D006509:Hepatitis B / Q000821:virology; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics*; D019694:Hepatitis B, Chronic / Q000201:enzymology / Q000821:virology*; D006801:Humans; D008113:Liver Neoplasms / Q000201:enzymology / Q000821:virology*; D008297:Male; D008875:Middle Aged; D009154:Mutation; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D040901:Proteomics; D017422:Sequence Analysis, DNA; D053719:Tandem Mass Spectrometry; D014758:Viral Core Proteins / Q000235:genetics*
D006514:Hepatitis B Surface Antigens; D014758:Viral Core Proteins; D008058:Dihydrolipoamide Dehydrogenase